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Resumo
Objetivos. Descrever e discutir a evolução do finan-
ciamento da assistência farmacêutica no Sistema 
Único de Saúde – SUS. Métodos. Foram identifica-
dos os valores alocados para aquisição de medica-
mentos, para o Programa Farmácia Popular e para 
estruturação de serviços farmacêuticos públicos. Os 
valores referentes ao financiamento da União, por 
meio do Ministério da Saúde, foram obtidos do sis-
tema Siga Brasil e, dos Estados, do Distrito Federal 
e dos municípios, do Sistema de Informações sobre 
Orçamentos Públicos em Saúde – SIOPS. Resulta-
dos. Entre 2005 e 2009 houve aumento de 65,3% 
nos recursos financeiros da União para aquisição 
de medicamentos. No mesmo período, ampliou-se 
o volume de transferências feitas às esferas sub-
nacionais. Verificou-se que os Estados e o Distrito 
Federal aumentaram em 112,4% o volume de recursos 
próprios alocados no financiamento de medicamen-
tos e que para os municípios este crescimento foi de 
22,7%. Em 2008, a participação das despesas com 
medicamentos em relação às despesas com saúde foi 
de 7,8%. O gasto total com medicamentos em 2009 
foi de 8,9 bilhões de reais. Observou-se aumento de 
20,6 vezes no valor alocado no Programa Farmácia 
Popular e, no caso dos recursos destinados à estru-
turação de serviços, crescimento de 41,6%, chegando 
a 10,1 milhões de reais em 2009. Conclusão: Houve 
ampliação do financiamento de medicamentos no 
SUS entre 2005 e 2009. 
Palavras-chave: Financiamento da Saúde; Assistên-
cia Farmacêutica; Gastos em Saúde; Sistema Único 
de Saúde.
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Abstract
Objectives. To describe and discuss developments 
in the financing of pharmaceutical services in the 
Brazilian public health system – SUS. Methods. 
The amounts allocated for drug procurement, for 
the Farmácia Popular Program and for structuring 
of public pharmaceutical services were identified. 
The values  regarding the financing of the Federal 
government were obtained from the Siga Brasil 
database. Data regarding states, Federal District 
and municipalities were obtained from Information 
System on Public Health Budget – SIOPS. Results. 
Federal funds for drugs purchasing increased by 
65.3% between 2005 and 2009. In the same period, 
the volume of transfers made to the subnational 
levels increased. It was found that the states and 
the Federal District have increased by 112.4% the 
volume of own resources allocated to the financing 
of drugs and for municipalities this growth was 
22.7%. In 2008, the share of drug expenses in rela-
tion to expenditure on health was 7.8%. The total 
drug spending in 2009 was 8.9 billion reais. There 
was an increase of 20.6 times of the amount alloca-
ted in the Farmácia Popular Program, and a growth 
of 41.6% in the resources destined to structuring 
services, which reached 10.1 million reais in 2009. 
Conclusion. there was expansion of the funding of 
medicines in SUS between 2005 and 2009.
Keywords: Financing; Health; Pharmaceutical Ser-
vices; Health Expenditures; Unified Health System.
Introduction
One of the most discussed subjects in public health 
nowadays is the financing of healthcare. Funding is a 
process of collecting monetary resources which will 
be directed to the execution of expenses, to carry 
out an investment or to achieve a certain objective 
(Brazil, 2009).
According to World Health Organization – WHO, 
the way healthcare systems are financed determine 
if people will be able to get healthcare and if they will 
face financial problems as a result of seeking care. 
Therefore, the planning and implementation of a 
proper funding system are essential in the pursuit 
of universal coverage (CARRIN et al., 2007; CARRIN 
et al., 2008; EVANS et al., 2010).
Universality implies in equal chances of access 
and protection from financial risk and great deman-
ds for the ones responsible for healthcare funding 
(CARRIN et al., 2007). That is why funding is being 
regarded as one of the biggest challenges to the 
implantation of universal systems. A recent evalu-
ation of Brazilian’s National Health System – SUS, 
shows that, in spite of advances in several areas 
and an overall improvement in health standards in 
the country, insufficient funding is a key factor for 
inappropriate infrastructure in primary care, as well 
as shortage of employees in hospitals (JURBERG, 
HUMPHREYS, 2010).
Regarding pharmaceutical care, not much is 
known about the population’s access to drugs. Once 
the under funding of the system is admitted, one 
also expects to find problems in drugs offer, not only 
regarding availability, but also in relation to the ra-
tionality of use and management of pharmaceutical 
services. These problems were confirmed by  some 
studies in the last few years (PAN-AMERICAN HE-
ALTH ORGANIZATION et al., 2005; WORLD BANK, 
2007; VIEIRA, 2008).
There was remarkable progress in legal marks 
with the publication of the Drugs National Policy – 
PNM (in Portuguese) in 1998 (BRAZIL, 2001) and the 
Pharmaceutical Care National Policy – PNAF in 2004 
(BRAZIL, 2004), which established, in a way, both the 
vision and the mission for the area in Brazil. PNM 
defines pharmaceutical care as a “group of activities 
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related to drugs, designed to support health actions 
demanded by a community. It includes the supply of 
medicines in each and every step; the conservation 
and control of quality, safety and therapeutic effi-
cacy of the drug; monitoring and evaluation of its 
use; gathering and advertising information on drugs 
and permanent education of health professionals, 
patients and community in order to ensure rational 
use of medicine” (BRAZIL, 2001).
The funding of pharmaceutical care for all of the 
activities depicted on PNM, likewise SUS funding, 
is provided by the Brazilian Government, 26 States, 
Federal District and 5,564 municipalities. The extent 
of political and administrative decentralization of 
the healthcare system reveals the complexity of 
this process (VIEIRA, 2010) and the necessity of 
analyzing the role on each level of the Government. 
Therefore, the objective of this article is to describe 
and discuss the evolution of pharmaceutical care 
funding at SUS.
Material and Methods
Data about the values assigned to drug care at 
SUS during the period from 2005 to 2009 were 
extracted from two information systems which 
are freely accessible through the internet: a) Siga 
Brasil, administered by the Senate, which discloses 
the government budget1; and b) Healthcare Public 
Budget Information System – SIOPS, administered 
by the Ministry of Health, which unveils data from 
the States, Federal District and Municipalities re-
garding revenue and healthcare expenses.
In the Federal Government budget, the following 
items were considered expenses for the acquisition 
of drugs: a) 6,031 – Immunobiological Drugs for Dise-
ase Prevention and Control; b) 4,295 – Hematological 
Diseases Patients’ Care; c) 6,142 – Coagulopathy Pa-
tients’ Care; d) 20AE – Promotion of Pharmaceutical 
Care and Strategic Input for Primary Healthcare; e) 
4,368 – Promotion of Pharmaceutical Care and Input 
for Strategic Healthcare Programs ; f) 4,370 – Drugs 
Program for  HIV/Aids and other STD Patients; g) 
4,705 – Support for the Acquisition and Distribution 
of Exceptional Drugs; and h) 20BA – Prevention, 
Preparation for and Management of the Influenza 
pandemic. In addition, the settled values in actions 
7,660 (Implantation of Popular Pharmacies) and 
8,415 (Popular Pharmacies’ Maintenance and Mana-
gement), expenses made on the Popular Pharmacy 
Program, were also included, as well as the actions 
0804 and 20AH – Support to Public Pharmacy Care 
Organization, which includes expenditure on Con-
tinuing Education, promotion of rational medicine 
use and organization of care units.
Data collection at Siga Brasil was made per year 
in the universe “LOA – executed expenses”, program, 
action, application mode and values applied.2 A 
search filter was applied – “National Health Fund” 
– in order to guarantee that only values applied on 
programs and actions under Health Ministry’s bud-
getary responsibility were collected.
For States and Federal District, applied expenses 
data gathered in the SIOPS were consulted at the 
system’s site, as follows3: States > Informed Data > One 
or more accounting codes consultation, by economic 
category, for a State, year or historical series > Year = 
(select), time span = annual, UF = weld all UFs,4 Type 
= Expense, Folder = Direct Administrative Expense – 
Health and Indirect Administrative Expense – Health, 
Phase = settled expenditure, accounting classifica-
tion = 3.3.3.90.30.00.01 and 3.3.3.90.30.09.00 – Drugs 
direct application, 3.3.3.40.00.0001 – Municipalities 
transfers and 3.3.3.90.32.03.01 – direct application of 
materials for free distribution (medicine). Financial 
resources considered as belonging to the States and 
Federal District were the amounts allocated without 
transfers, i.e., the sum of the amounts paid in the 
accounting classifications described minus values 
transferred by Brazilian Government and by the 
Municipalities.
When it came to municipalities, the path used in 
1 Senate. Siga Brasil. Available at: http://www9.senado.gov.br/portal/page/portal/orcamento_senado.
Access in October 4th 2010.
2 The term “applied” corresponds to the budget execution in which the Public Administration acknowledges that the service or product 
was delivered and, therefore, the commitment of paying the supplier.
3 Ministry of Health. Healthcare Budget Information System – SIOPS. Available at: http://siops.datasus.gov.br. Access in October 7th 2010.
4 UF stands for”Unidade da Federação” – Federation Unit
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the SIOPS was: Municipalities > Informed data > One 
or more accounting code consultation by economic 
category, for a Municipality, by year or historical series 
> year = (select) > period = yearly > UF = weld all UFs, 
type = expense, folder = Direct administrative expen-
se – Healthcare and Indirect administrative expense 
– Healthcare, phase = settled expenditure, accounting 
classification = 3.3.3.90.30.00.01 and 3.3.3.90.30.09.00 
– Drugs direct application, 3.3.3.90.32.03.01 – Direct 
application of free distribution material (drugs), 
3.3.3.30.00.00.01 – States and Federal District trans-
fers and 3.3.3.40.00.00.01 – Transfers to Municipali-
ties. Established criterion considered as municipal 
resource all the values allocated without transfers, 
i.e., the sum of the amounts paid in the accounting 
classifications described minus values transferred by 
the Brazilian Government and by the States. 
The updating of data transmission on revenue 
and healthcare  expenses into SIOPS by States, the 
Federal District and Municipalities was verified 
with the purpose of acknowledging the universe of 
federal units to whom the resources were allocated.
To make comparisons possible between allocated 
values (total value in transfers and direct applications) 
in the period of 2005 to 2009, discarding the inflation, 
the settled values were deflated to 2009 using the 
Broad Price Index to Consumers – IPCA, obtained 
for every year on the Applied Economics Research 
Institute – IPEA website.5 An exploratory analysis of 
data was performed, resulting in tables and figures.
Results
Between 2005 and 2009 there was a 65.3% raise in 
financial resources allocated by the Brazilian Gover-
nment via Healthcare Ministry for the acquisition 
of medicines for SUS: from 3.4 Billion reais declared 
in 2009 to 5.7 Billion reais last year.
On the same period, the volume of transfers to 
subnational levels raised. Transfers to States and the 
Federal District responded for 40.6% of the Federal 
Government in 2005 and 45.3% in 2009. See table 1.
At the Municipalities, federal transfers respond-
ed for 4.5% of allocated resources of the Government 
for medicines in 2005. This share jumped to 11.3% in 
2009. Simultaneously, the direct application share 
on the Healthcare Ministry budget fell from 50.2% 
to 41.8% according table 1.
To analyze the States’, Federal District’s and Mu-
nicipalities’ resources allocation it was important to 
check their legal status regarding declared data on 
revenue and expenses with healthcare actions and 
services. This is a function of their providing data 
within legal deadlines  through SIOPS. Table 2 de-
picts the situation regarding data transmission. Only 
regular ones were considered in the present study.
It can be observed that nearly all municipalities 
transferred data until 2008 (more than 99%) and 
in 2009, until the data was compiled, 97.9% had 
transferred. In States and Federal District, 100% 
were in regular situation until 2008, and only two 
States didn’t transfer data in 2009.
Financial resources applied on medicine by 
states and municipalities were calculated from 
the data transferred by States and Federal District 
and considering the values assigned by the Union 
in transfers to States, as well as values declared by 
Municipalities through SIOPS, as shown in figure 1.
It can also be noted in Figure 1 that, between 2005 
and 2009, States and Federal District increased the 
amount of own resources destined financing medicine 
acquisition in 112.4%, going from 773.7 million reais 
in 2009 to 1.6 billion reais last year. As regarding 
transfers from States to Municipalities, their value 
raised significantly from 2005 to 2006 then fell, so 
that the value transferred in 2009 was 22.7% smaller 
than 2005’s. On the other hand, during the same pe-
riod, transfers from Municipalities to States raised 
from 2.8 million in 2005 to 9.5 million this year, an 
increase of 232.1%. Direct applications raised 95.4%.
Regarding Municipalities, their resources ap-
plied in the financing of medicine acquisition 
passed from 1.3 billion reais in 2005 to 1.6 billion in 
2009, a 22.7% raise, according to Figure 2.
It’s also noted that Municipalities also raised 
the amount of resources transferred to other Mu-
nicipalities to finance medicine purchasing in the 
period of 2005 to 2009, going from 1 million to 10.9 
5 Applied Economics Research Institute – IPEA. Ipeadata (http://www.ipeadata.gov.br) > Macroeconomics > Frequently used series > Anual 
IPCA inflation > Operate > Operation = None > Beginning = 2005, Ending = 2009, New periodicity = Annual, Method = period ending, new 
base = 2009.
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Table 1 - Amounts paid off Federal Budget per modality of use in actions that funded drugs purchase. Brazil, 
2005-2009
Application Mode
R$ declared in 2009
2005 2006 2007 2008 2009
Transfers to states and 
Federal District
1,387,390,058.19 2,034,129,159.35 2,036,988,199.71 2,251,258,231.98 2,560,249,045.59
Transfers to municipalities 154,695,697.09 403,856,766.21 554,298,841.12 635,594,008.74 640,407,375.73
Transfers to private non-
profit organizations
119,028,413.61 7,507,040.14 14,297,183.56 23,652,715.82 24,770,062.92
Transfers abroad 41,607,195.68 69,253,601.76 160,764,322.53 164,964,406.20 66,425,664.27
Direct applications 1,716,594,105.76 1,918,849,345.96 2,136,319,858.86 2,106,811,181.15 2,360,114,976.95
Direct applications – internal 
operations
- 1,294,506.34 1,755,318.98 241,330.89 118.12
Total 3,419,315,470.33 4,434,890,419.78 4,904,423,724.75 5,182,521,874.77 5,651,967,243.58
Source: made by authors based on data from Federal Budget collected at ‘SIGA Brasil’, Federal Senate’s information system.
Tabela 2 - Situação de transmissão de dados sobre receitas e despesas com ações e serviços públicos de saúde. 
Brasil, 2005 - 2009
Year
Municipalities States and Federal District
Total Regular % of regular Total Regular % of regular
2005 5,562 5,558 99,9 27 27 100,0
2006 5,562 5,556 99,9 27 27 100,0
2007 5,562 5,548 99,7 27 27 100,0
2008 5,562 5,528 99,4 27 27 100,0
2009 5,563 5,444 97,9 27 25 92,3
Source: made by authors based on data from Healthcare Public Budget Information System – SIOPS. Data collected on 10/07/2010.
million reais, i.e., an increase of 901.3%. Direct ap-
plication also increased 51.3%.
Table 3 presents a summary of the amount of 
resources applied by Federal Government, States 
and Municipalities to finance medicine purchasing.
The participation of Federal Government in 
medicine funding was virtually stable between 2005 
and 2009, passing from 61.8% to 63.2%. Simultane-
ously, States participation increased from 14% to 
18.4%, and Municipalities’ decreased from 24.2% to 
18.4%. In total, SUS resources for medicine acquisi-
tion increased 61.6%.
In 2008, consolidated data of healthcare spend-
ing became available. These data show that SUS ex-
penses with public actions and healthcare services 
reached 108.8 billion reais; total expenses with 
medicine funding were 8.4 billion (7.8%).6
In the Popular Pharmacy Program, values al-
located by the Health Ministry from 2005 to 2009 
increased 20.6 times, from 21.2 million reais (2009 
values) to 437.8 million. Resources destined to the 
organization of public pharmaceutical services 
presented a smaller growth: they increased 41.6%, 
from 7.1 million reais in 2005 to 10.1 million in 2009.
6 The total amount of SUS public actions and healthcare services was obtained from the sum of Federal, State and Municipalities expenses 
in 2008, published in the following brochure: Brazil, Health Ministry, Sistema de Informações sobre Orçamentos Públicos em Saúde – 
SIOPS. Healthcare public expenses informations system. Available at http://siops.datasus.gov.br/Documentacao/VisGastosPúblicosSaúde.
pdf. Access in October 11th 2010.
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Table 3 - Paid values by all government levels in medicine funding actions. Brasil, 2005-2009
Administration level
R$ declared in 2009
2005 2006 2007 2008 2009
Union 3.419.315.470,33 4.434.890.419,78 4.904.423.724,75 5.182.521.874,77 5.651.967.243,58
States 773.788.463,01 798.051.970,66 1.119.204.976,75 1.826.621.914,63 1.643.653.598,41
Municipalities 1.337.107.470,41 1.189.580.030,88 997.599.717,48 1.796.132.014,80 1.640.693.875,67
Total 5.530.211.403,76 6.422.522.421,32 7.021.228.418,98 8.805.275.804,20 8.936.314.717,66
Source: made by authors based on data from Federal Budget collected at ‘SIGA Brasil’, Federal Senate’s information system, and Healthcare Public Budget Information 
System – SIOPS.
Figure 1 - Financial resources allocated by states and Federal District to the funding of drugs acquisition. Brazil, 
2005-2009
Description
R$ declared in 2009
2005 2006 2007 2008 2009
Total expenses
Direct applications 2.151.777.264,56 2.783.280.778,87 3.113.235.735,18 4.064.722.999,50 4.203.900.409,71
Transfers to municipalities 12.254.548,45 52.611.785,64 46.642.101,36 20.133.880,89 9.477.450,34
Total 2.164.031.813,01 2.835.892.564,52 3.159.877.836,54 4.084.856.880,39 4.213.377.860,05
Transfers revenues
Received federal resources 1.387.390.058,19 2.034.129.159,35 2.036.988.199,71 2.251.258.231,98 2.560.249.045,59
Received municipal resources 2.853.291,80 3.711.434,50 3.684.660,08 6.976.733,78 9.475.216,05
Total 1.390.243.349,99 2.037.840.593,85 2.040.672.859,79 2.258.234.965,76 2.569.724.261,64
Own Funding
States and Federal District resources 
minus received transfers 773.788.463,01 798.051.970,66 1.119.204.976,75 1.826.621.914,63 1.643.653.598,41
Source: made by authors based on data from Healthcare Public Budget Information System – SIOPS. Data collected on 10/07/2010.
Figure 2 - Financial resources allocated by municipalities to the funding of drugs acquisition. Brazil, 2005-2009
Description
R$ declared in 2009
2005 2006 2007 2008 2009
Total expenses
Direct applications 1.500.117.295,37 1.641.775.313,64 1.593.363.987,24 2.442.346.961,71 2.270.217.700,46
Transfers to states 2.853.291,80 3.711.434,50 3.684.660,08 6.976.733,78 9.475.216,05
Transfers to municipalities 1.087.128,77 561.834,59 1.492.012,64 2.536.208,93 10.885.785,23
Total 1.504.057.715,95 1.646.048.582,73 1.598.540.659,96 2.451.859.904,43 2.290.578.701,74
Transfers revenues
Received federal resources 154.695.697,09 403.856.766,21 554.298.841,12 635.594.008,74 640.407.375,73
Received state resources 12.254.548,45 52.611.785,64 46.642.101,36 20.133.880,89 9.477.450,34
Total 166.950.245,54 456.468.551,86 600.940.942,48 655.727.889,63 649.884.826,07
Own Funding
Municipalities resources minus 
received transfers 1.337.107.470,41 1.189.580.030,88 997.599.717,48 1.796.132.014,80 1.640.693.875,67
Source: made by authors based on data from Healthcare Public Budget Information System – SIOPS. Data collected on 10/07/2010.
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Discussion
In SUS, as in several other countries, a growth in 
medicine expenses was noted. This paper verified 
an increase of 65.3% in the volume of resources 
allocated by the Federal Government to medicine 
purchasing between 2005 and 2009.7 This trend 
was already observed in a study that analyzed He-
alth Ministry’s expenses with pharmaceutical care 
for the period of 2002 to 2007, pointing out that 
the 2007‘s expense was 3.2 times the one in 2002 
(Vieira, 2009).
Part of this growth is explained by the expen-
ses destined to the management of the influenza 
pandemic in 2009, when 542.9 million reais were 
allocated to pharmaceutical care. It is also possible 
that this raise is related to an increase in offer, since 
recent evidences suggest significant efficiency gain 
in Health Ministry pharmaceutical care programs 
(Aurea et al, 2010).
The increase in transfers to States, Federal 
District and Municipalities is in consonance with 
the pharmaceutical care decentralization policy, 
observed especially since 2005 when Health Mi-
nistry increased resource transfers, mainly to Mu-
nicipalities, to finance primary care drugs (Brasil, 
2005). This explains the 314% raise in the amount 
of resources transferred from the Health Ministry 
to Municipalities between 2005 and 2009, as well as 
the decrease in direct applications in the Ministry’s 
budget (from 50.2% in 2005 to 41.8% in 2009). The 
Health Ministry stopped buying in a centralized 
purchase a great deal of drugs used in primary care 
treatment and started to shift resources so that 
States, Federal District and Municipalities in special 
purchase drugs used in their services.
In the transfers from Federal Government to 
States and Federal District there was also growth, 
but with smaller impact. Its share on the Health 
Ministry budget – 40.6% in 2005 – increased to 
45.3% in 2009. Here an opposite process to the one 
observed for the acquisition of primary care drugs 
can be seen. States main responsibility is the co-
-financing and management of medicine purchases 
and dispensation at the Pharmaceutical Care Specia-
lized Component (Vieira, 2010). In the same period, 
centralization of the purchase of specific drugs by 
the Health Ministry was observed, since it also takes 
part in its funding (Brasil, 2006; Brasil 2009).
Health Ministry expenses with programs for 
purchasing this kind of drugs increased 252% from 
2003 to 2007 (Vieira, 2010). Therefore, purchase 
centralization was driven by economic matters: the 
drugs purchased are very expensive and generally 
are produced by only one manufacturer in Brazil. 
Centralizing acquisition increases the scale and 
offers a larger margin for price negotiation (Chalki-
dou et al, 2010).
When it comes to the allocation of financial re-
sources for medicine acquisition by States, Federal 
District and Municipalities, firstly it is necessary to 
clarify that data transmission about the expenses 
and receipts with public health services and actions 
through SIOPS has a declaratory nature instead 
of a mandatory one, even though a few legal cons-
traints were created; this encourages the supply of 
information.8 The agreed deadline for data trans-
mission of a given financial exercise is April 30th of 
the following year. As verified on table 2 for 2009, 
119 Municipalities and 2 States didn’t supply the 
system until the data collection date. The main im-
plication of this fact is that these entities’ allocated 
resources weren’t accounted and, consequently, the 
settled values were larger than the ones presented 
on this paper, even if the estimated difference is 
relatively small. Anyway, States, Federal District 
and Municipalities may, at any given time, supply 
or correct a financial exercise data. This fact has to 
be kept in mind, since comparison of values can be 
difficult in searches performed at different times, 
due to the system’s nature and operation – date of 
data collection at SIOPS can cause discrepancies.
As to the financing of drugs acquisition, the 
States and Federal District increased their own 
resources share in 112%, becoming the adminis-
trative sphere that increased the most its resource 
7 All values were converted in 2009 reais, applying the Broad Price to the Consumer Index – IPCA, to eliminate the inflation effect and to 
allow comparisons for the studied period.
8 For further information about the Public Healthcare Budget Information System – SIOPS: http://siops.datasus.gov.br/siops.php. Access 
in  April 17th 2011.
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contribution between 2005 and 2009, in percentage. 
Their direct application in drugs – when the state 
administration buys directly in the market, increa-
sed 95.4% in the period; at the same time, transfers 
to Municipalities decreased 22.7% and transfers 
received by Municipalities increased 232%. The fac-
tors responsible for this situation were probably an 
increase in demand and qualitative and quantitative 
changes in drugs list of the Pharmaceutical Care 
Specialized Component, such as the annexation of 
more drugs and of more valuable ones. Besides, the 
most probable hypothesis to explain the transfers’ 
context is the execution of the Pharmaceutical Care 
Basic Component (Brasil, 2010).
This Component is mainly under municipal 
management, but the three government spheres 
fund it. It may occur a pact between States and Mu-
nicipalities so that the first supply the resources, 
either by medicine production in public pharma-
ceutical laboratories, as it is the case in São Paulo 
and Minas Gerais, or by association mechanisms for 
acquisition, as in the establishment of consortium 
in Paraná (Cosendey et al, 2000).
Regarding the Municipalities funding, drugs 
acquisition with their own resources grew the least 
between 2005 and 2009 (22.7%). This was due mainly 
to an increase in transfers for other Municipalities 
(901%) and to States (232%). Direct application grew 
around 51.3%. There is evidence that, in that period, 
the role of States got bigger in the execution of Phar-
maceutical Care Basic Component and that inter-
-municipal arrangements are being made to allow 
drugs purchasing. This is an interesting situation 
in order to reach an efficient use of resources: over 
70% of Brazilian Municipalities have less than 20 
thousand inhabitants and a low acquisition power 
due to the small scale of drugs’ purchasing.
Concerning SUS’ global funding for medicine 
purchase (table 3), it’s important to point out that 
the presented values do not include expenses fi-
nanced by the Health Ministry through hospital 
attention and chemotherapy procedures because the 
financing is done for a group of activities, including 
medicine, which makes it difficult to identify values 
attributable only to these products.
Still, an increase of 61.6% in SUS’ resources 
between 2005 and 2009 for medicine purchase was 
observed. A recent study from the Executive Group 
for National Healthcare Accounting, applying the 
final medicine consumption method, i.e., medicine 
not used in healthcare institutions, showed real 
growth of 27% in Public Administration consump-
tion between 2005 and 2007 (Brazil – IBGE, 2009).
This increase is in line with a growth trend in 
several countries. In Canada, spending per capita 
with prescribed oral ingestion solids increased 
10% yearly in most provinces from 1998 to 2004, 
faster than the economic growth for the same period 
(Morgan, 2005). In USA the increase in spending 
with drugs sold under prescription was 4.9% from 
2006 to 2007 and hit the 227.5 billion dollars mark 
(Hartman et al, 2009). In Mexico, total spending with 
medicines in 2007 responded for 21% of healthcare 
spending (Moise, 2008).
In Brazil, despite the increase in SUS’ spending 
with drugs between 2005 and 2009, its share in 
total healthcare spending seems lower than neces-
sary (7.8% in 2008). Data from the National Survey 
from Residence Sampling – PNAD in 2008 showed 
that 48.9% of the interviewed that needed medicine 
couldn’t get them for free.9 Besides that, in 2007, fa-
milies financed 90% of final medicine consumption 
while Public Power financed the other 10% according 
to the health satellite-account (Brazil – IBGE, 2009).
The large difference can be explained by the fact 
that, in Public Administration, drugs are dispensed 
only upon presentation of a medical prescription; 
prices generally are lower than the ones paid by 
consumers and private institutions; Public Admi-
nistration chooses drugs that are offered, promo-
ting rational medicine use; but certainly the public 
healthcare system is under funded.
In order to compare SUS drugs funding with 
other countries, it’s assumed that 1 international 
dollar corresponds to 1.56 reais, considering that 
in 2009 the World Bank released figures for the 
9 PNAD data can be obtained at Brazilian Institute for Geography and Statistics – IBGE (http://www.ibge.gov.br). Path is: Population>PN
AD>Supplements>PNAD 2008 – Brazilian Health Overview> Microdata>Data. Access in: October 11th 2010.
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valued 2 billion international dollars (World Bank, 
2010) and that the official source of Brazilian GNP 
figures is IBGE, which estimated it (in 2009) at 3.1 
billion reais10. In this case, the amount allocated 
to drugs acquisition by SUS (8.9 billion reais) is 
equivalent to 5.7 billion international dollars, whi-
ch corresponds to a per capita spending of 29.92 
international dollars.11 This value is far below the 
amount allocated by Canada and Italy, 754 and 528 
international dollars per capita on the same year, 
respectively, even when considered that in those 
countries private spending is included (OECD, 2010).
As to the Popular Pharmacy Program, data re-
vealed a great increase in resource allocation. It is 
important to point out that, considering the Brazi-
lian Government budget, it’s not possible to infer the 
resources applied in the States’ and Municipalities’ 
pharmacies maintenance and the resources applied 
to subsidize drugs offered to the public in accredited 
private pharmacies. It’s assumed that resources ap-
plied in subsidies respond for the greater part of the 
assets used in the program, due to the large increase 
in the number of accredited private pharmacies in 
the last few years (Brasil, 2011).
Regarding assets applied by the Health Ministry 
in the management of pharmaceutical care, in 2009 
they responded for 0.18% of drugs acquisition total 
(10 million reais). Even though there are no data for 
States, Federal District and Municipalities in this 
matter, it is possible to notice that resources applied 
in improving management are insufficient, as there 
are serious problems resulting in medicine waste 
and compromising access (Pan-American Health Or-
ganization, 2005; World Bank, 2007; Vieira, 2008).
According to Tobar (2008), the best medicine 
offer strategies are the ones that manage to univer-
salize access to goods and services, while reducing 
costs and improving resource allocation efficiency.
There is a long way to go for Brazil in order to 
ensure access to and rational use of medicines, but 
surely some improvements had already taken place. 
More effort is necessary in order to improve phar-
maceutical care management and to ensure efficient 
use of resources applied in drugs purchasing and 
the sustainability of SUS.
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